OPRX vs MCK

For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.

8% revenue growth year-over-year, versus 16. 2% for McKesson Corporation (MCK). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 0x trailing P/E (6. 9x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

0x versus McKesson Corporation at 28. 9x. On forward P/E, OptimizeRx Corporation is actually cheaper at 6. 9x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to -86. 5% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: MCK returned +351. 9% versus OPRX's +105. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 5185% more volatile than MCK relative to the S&P 500.

By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.

8% versus 16. 2% for McKesson Corporation (MCK). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus 1. 2% for MCK. At the gross margin level — before operating expenses — OPRX leads at 67. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 6.

9x forward P/E versus 19. 1x for McKesson Corporation — 12. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 162. 8% to $17. 00.

In this comparison, MCK (0.

4% yield) pays a dividend. OPRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +351. 9%, OPRX: +105. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.